尾状核脑深部电刺激治疗难治性耳鸣的I期试验
这项开放标签、非随机I期试验评估双侧尾状核脑深部电刺激(DBS)治疗难治性耳鸣的疗效与安全性。6例受试者植入电极,5例完成分析,经5-13个月刺激优化后连续刺激24周。耳鸣功能指数(TFI)和耳鸣致残量表(THI)均显著改善,60%-80%受试者获临床显著获益,未见安全性问题。
要点
- 双侧尾状核DBS可显著改善难治性耳鸣的TFI和THI评分。
- 60%-80%受试者达到临床显著获益,疗效个体差异大。
- 执行功能、行为及听力安全性指标未见显著改变。
核心结论
- 双侧尾状核DBS治疗严重难治性耳鸣结果非常鼓舞,疗效显著但变异大,无安全性担忧。
研究设计与样本
- 开放标签、非随机I期试验,6例受试者植入DBS电极,5例提供完整可分析数据集。
- 刺激优化期5-13个月,随后连续尾状核刺激24周至终点。
主要发现
- TFI平均(SE)改善23.3(12.4),THI改善30.8(10.4),均具统计学显著性(Wilcoxon符号秩检验,单尾,α=0.05)。
- TFI应答者3例(下降≥13分),THI应答者4例(下降≥20分),治疗响应率60%-80%。
- 执行功能评分、FrSBe、听阈及词识别分数在连续刺激下无显著变化。
关键数值与推荐
- 主要疗效终点为耳鸣功能指数(TFI),次要疗效终点为耳鸣致残量表(THI)。
- 临床显著应答标准:TFI下降≥13分,THI下降≥20分。
- 安全性评估包括执行功能复合z评分、FrSBe、纯音听阈(0.5、1、2、3、4、6 kHz)和词识别分数。
临床怎么用
- 对于严重难治性耳鸣,双侧尾状核DBS可能是一种有前景的干预手段,但需进一步II期试验验证。
- 未来试验可通过靶点优化缩短刺激优化期并提高疗效一致性。
局限性
- 开放标签、非随机设计,样本量小(5例分析),疗效变异大。
- 1例因与刺激无关的自杀倾向退出,另1例发生与刺激无关的自杀未遂严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this open-label, nonrandomized trial was to evaluate the efficacy and safety of bilateral caudate nucleus deep brain stimulation (DBS) for treatment-resistant tinnitus. METHODS: Six participants underwent DBS electrode implantation. One participant was removed from the study for suicidality unrelated to brain stimulation. Participants underwent a stimulation optimization period that ranged from 5 to 13 months, during which the most promising stimulation parameters for tinnitus reduction for each individual were determined. These individual optimal stimulation parameters were then used during 24 weeks of continuous caudate stimulation to reach the endpoint. The primary outcome for efficacy was the Tinnitus Functional Index (TFI), and executive function (EF) safety was a composite z-score from multiple neuropsychological tests (EF score). The secondary outcome for efficacy was the Tinnitus Handicap Inventory (THI); for neuropsychiatric safety it was the Frontal Systems Behavior Scale (FrSBe), and for hearing safety it was pure tone audiometry at 0.5, 1, 2, 3, 4, and 6 kHz and word recognition score (WRS). Other monitored outcomes included surgery- and device-related adverse events (AEs). Five participants provided full analyzable data sets. Primary and secondary outcomes were based on differences in measurements between baseline and endpoint. RESULTS: The treatment effect size of caudate DBS for tinnitus was assessed by TFI [mean (SE), 23.3 (12.4)] and THI [30.8 (10.4)] scores, both of which were statistically significant (Wilcoxon signed-rank test, 1-tailed; alpha = 0.05). Based on clinically significant treatment response categorical analysis, there were 3 responders determined by TFI (≥ 13-point decrease) and 4 by THI (≥ 20-point decrease) scores. Safety outcomes according to EF score, FrSBe, audiometric thresholds, and WRS showed no significant change with continuous caudate stimulation. Surgery-related and device-related AEs were expected, transient, and reversible. There was only one serious AE, a suicide attempt unrelated to caudate neuromodulation in a participant in whom stimulation was in the off mode for 2 months prior to the event. CONCLUSIONS: Bilateral caudate nucleus neuromodulation by DBS for severe, refractory tinnitus in this phase I trial showed very encouraging results. Primary and secondary outcomes revealed a highly variable treatment effect size and 60%-80% treatment response rate for clinically significant benefit, and no safety concerns. The design of a phase II trial may benefit from targeting refinement for final DBS lead placement to decrease the duration of the stimulation optimization period and to increase treatment effect size uniformity.Clinical trial registration no.: NCT01988688 (clinicaltrials.gov).
引用
- Cheung SW, Racine CA, Henderson-Sabes J, et al. Phase I trial of caudate deep brain stimulation for treatment-resistant tinnitus. J Neurosurg. 2019. PMID: 31553940. doi:10.3171/2019.4.JNS19347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。